The angiopoietin-like proteins (ANGPTLs) 3, 4 and 8 have emerged as key regulators of plasma lipid metabolism by serving as potent inhibitors of the enzyme lipoprotein lipase (LPL). In this review, we provide an integrated picture of the role of ANGPTL3, ANGPTL4 and ANGPTL8 in lipid metabolism by focusing on their impact on LPL activity and plasma triglyceride clearance during physiological conditions such as fasting, refeeding, exercise and cold exposure.
INTRODUCTION
The angiopoietin-like proteins (ANGPTL1-8) are secreted glycoproteins composed of an N-terminal coiled-coil domain and a fibrinogen-like C-terminal domain. Despite their common architecture, the eight family members carry distinct physiological functions, with suggested roles in angiogenesis, expansion of stem cells, inflammation, tissue remodeling and lipid metabolism [1, 2] . A shared feature of ANGTPL3, ANGPTL4 and ANGPTL8 is their involvement in lipoprotein metabolism. Indeed, genetic studies have revealed pronounced effects of common variants in the ANGPTL3, ANGPTL4 and ANGPTL8 genes on plasma lipid levels [1,3 & ,4] . Functional studies have indicated that ANGPTL3, ANGPTL4 and ANGPTL8 influence plasma lipid levels by inhibiting the activity of extracellular lipases, including the structurally related lipoprotein lipase (LPL), hepatic lipase, endothelial lipase and pancreatic lipase [4] [5] [6] [7] [8] [9] . In this review, we aim to provide an integrated picture of the impact of the ANGPTLs on lipid metabolism, with special emphasis on the functional roles of ANGPTL3, ANGPTL4 and ANGPTL8 in governing the activity of LPL during physiological conditions such as fasting, refeeding, exercise and cold exposure.
ANGIOPOIETIN-LIKE 3
ANGPTL3 was linked to lipid metabolism via identification of an Angptl3-mutant KK/San mouse strain characterized by abnormally low plasma triglycerides [10] . Since then, biochemical and animal studies have convincingly established that ANGPTL3 serves as an inhibitor of LPL and thereby reduces plasma triglyceride clearance, partially explaining the hypolipidemic phenotype of the KK/San mice [6, [10] [11] [12] . Consistent with these findings, genomewide association studies as well as dedicated studies of common variants in and near the ANGPTL3 gene locus have repeatedly associated ANGPTL3 with plasma triglyceride and plasma HDL cholesterol levels [13] [14] [15] [16] [17] [18] [19] . Furthermore, exome sequencing in patients with severe familial combined hypolipidemia -a condition characterized by low plasma LDL cholesterol, HDL cholesterol and triglyceride levels -revealed rare loss-of-function mutations in the ANGPTL3 gene [20, 21] . Affected individuals exhibit markedly elevated plasma LPL activity and LPL mass [20] .
Apart from inhibiting LPL, there is some evidence that ANGPTL3 also interferes with the activity of endothelial lipase [9, 22 && ]. Endothelial lipase mainly carries phospholipase activity and lowers plasma HDL cholesterol levels [23] [24] [25] . Treatment of mice with a monoclonal antibody against ANGPTL3 significantly reduced plasma HDL cholesterol levels in wild-type but not endothelial lipase-deficient mice [22 && ]. In line with human genetic data and consistent with inhibition of endothelial lipase by ANGPTL3, several studies have reported a positive association between plasma ANGPTL3 levels and plasma HDL [9, 20, 23 shown that differences in tissue LPL activity levels and VLDL-derived triglyceride uptake between wild-type and Angptl3 -/-mice are most pronounced in the postprandial state, suggesting that ANGPTL3 mainly affects LPL activity and plasma triglyceride levels shortly after feeding. Upon feeding, loss of Angptl3 led to a significant increase in LPL activity in postheparin plasma and several tissues [12, 29 && ]. Intriguingly, however, the increase in LPL activity was accompanied by decreased postprandial uptake of VLDL-derived triglycerides into white adipose tissue (WAT) and increased uptake into heart, muscle and brown adipose tissue (BAT) [29 && ]. On the basis of these data, it was proposed that ANGPTL3 promotes the replenishment of WAT triglyceride stores upon refeeding by specifically inhibiting the uptake of circulating triglycerides into heart and BAT [29 && ]. These data underscore that measurement of LPL activity in postheparin plasma or in tissue biopsies may not always give a proper impression of functional LPL activity at the endothelium [30] . For now, the underlying mechanism for this tissue-specific action of ANGPTL3 remains unclear. One possibility is that it somehow has to do with the ill-defined interaction between ANGPTL3 and ANGPTL8. ANGPTL3 and ANGPTL8 have been suggested to interact to effectively inhibit LPL [4, 29 && ]. Clearly, additional studies are required to better understand the tissue-specific action of ANGPTL3.
As indicated above, carriers of ANGPTL3 lossof-function mutations have low plasma LDL cholesterol levels [20, 21] . In addition, a positive association was found between plasma ANGPTL3 and plasma LDL cholesterol [26 & ]. These findings have led to exploration of the potential mechanism underlying the relation between ANGPTL3 and LDL [20,21, Locally expressed ANGPTL4 assures that tissues with increased metabolic demand receive an adequate supply of triglycerides by specifically shuttling plasma triglycerides to the tissue in need.
ANGPTL4 is the central component of a fatty aciddriven feedback mechanism that regulates plasma triglyceride hydrolysis and subsequent tissue fatty acid uptake in response to changes in lipid availability and cellular fuel demand.
The profound impact of the angiopoietin-like proteins on plasma lipid levels has sparked interest of pharmaceutical companies into angiopoietin-like proteins as therapeutic targets for the treatment of dyslipidemia.
suggested to act as a molecular bridge between lipoproteins and the hepatocyte cell surface, which could promote the clearance of VLDL remnants and reduce the fraction of VLDL that is converted into LDL [31 && ,33,34] . Although the impact of ANGPTL3 on LDL cholesterol levels via LPL complements the established function of ANGPTL3 as an inhibitor of plasma triglyceride clearance, further studies should clarify how inhibition of LPL by ANGPTL3 impacts VLDL remnant clearance and plasma levels of LDL cholesterol. Furthermore, it remains to be determined how the role of ANGPTL3 in triglyceride distribution upon refeeding can be linked to its effect on LDL and HDL cholesterol levels, which are both not substantially altered upon refeeding [35] . A final point of interest is the discrepancy between the stimulatory effect of ANGPTL3 on intracellular WAT lipolysis described in a number of studies and the purported inhibitory effect of ANGPTL3 on WAT lipolysis observed during the replenishment of WAT triglyceride stores upon refeeding [20, 29 && ,31 && ,32]. Answers to these questions may provide further insight into the functioning of ANGPTL3.
ANGIOPOIETIN-LIKE 4
ANGPTL4, originally referred to as fasting-induced adipose factor, is a glycosylated protein that is highly expressed in liver and adipose tissue and to a lesser extent in heart, skeletal muscle, intestine and several other tissues [7, 36, 37 && ]. Expression of ANGPTL4 is sensitively regulated by the fatty acid-activated peroxisome proliferator-activated receptors (PPARs) [36, [38] [39] [40] [14, 16] .
The inhibitory effect of ANGPTL4 on LPL activity has been extensively documented in numerous in vivo and in vitro studies [5, 12] . Several recent studies suggest that ANGPTL4 is the master regulator of plasma triglyceride metabolism during physiological conditions such as fasting, cold exposure and exercise [35, 37 && ,49 && ]. The data point to a scenario wherein ANGPTL4 is the central component of a feedback mechanism that regulates plasma triglyceride hydrolysis and subsequent tissue fatty acid uptake in response to changes in lipid availability and cellular fuel demand [35, 37 && ,40,49 && ,50]. According to this mechanism, Angptl4 expression is induced by elevated plasma free fatty acid levels via PPARs, subsequently leading to inhibition of LPL and decreased plasma triglyceride-derived fatty acid uptake [40, 49 && ]. In WAT, induction of ANGPTL4 during fasting leads to repression of LPL activity, thereby preventing lipid storage and ensuring adequate provision of lipid fuels to other tissues [35] . In skeletal muscle, ANGPTL4 is induced by exercise via elevated free fatty acids specifically in the nonexercising muscle, leading to reduced local uptake of plasma triglyceride-derived fatty acids to spare for use by exercising muscle [49 && ]. In exercising muscle, the free fatty acid-induced upregulation of ANGPTL4 is countered by AMP-activated protein kinase (AMPK)-mediated downregulation of ANGPTL4, promoting the use of plasma triglycerides as fuel for active muscles [49 && ]. In BAT, ANGPTL4 is markedly suppressed by cold exposure via activation of AMPK, enhancing LPL activity and uptake of plasma triglyceride-derived fatty acids [37 && ]. By contrast, ANGPTL4 is induced by cold in WAT, thereby limiting LPL activity and prioritizing fuel provision to BAT to generate heat [37 && ]. In addition to being important for physiological regulation of plasma triglyceride metabolism, there is evidence that ANGPTL4 is also implicated in certain clinical forms of hypertriglyceridemia. Specifically, ANGPTL4 may mediate the hypertriglyceridemia of nephrotic syndrome [51] .
Despite the strong genetic and experimental evidence for a key role of ANGPTL4 in plasma triglyceride metabolism, most studies have failed to find a significant correlation between plasma ANGPTL4 and plasma triglyceride levels [26 27, [52] [53] [54] [55] [56] . This result is somewhat surprising but does not refute an important function of ANGPTL4 in human lipid metabolism. The lack of association of plasma ANGPTL4 levels with plasma triglycerides might be explained by the inability of the employed ELISAs to detect N-terminal ANGPTL4 [56, 57] . An alternative explanation is that circulating ANGPTL4 is not exclusively responsible for regulation of LPL activity [50, 58, 59] . Indeed, recent studies are suggestive of a model in which ANGPTL4 may regulate LPL intracellularly and in the subendothelial space rather than along the capillary lumen [58, 60, 61] . Both circulating triglyceride-rich lipoproteins and glycosylphosphatidylinositol-anchored HDL-binding protein 1 -the protein responsible for translocation of LPL to the endothelial cell surface -prevent inhibition of LPL activity by ANGPTL4 [59, 62, 63] . Further studies should elucidate the exact molecular mechanism and location of inhibition of LPL by ANGPTL4.
In contrast to the clear inhibition of LPL, ANGPTL4 has not been reported to inhibit endothelial lipase, while the effects of ANGPTL4 on hepatic lipase have been contradictory [8, 12, 16] . Remarkably, a recent study provided evidence that ANGPTL4 inhibits pancreatic lipase in the intestinal tract and suggested that ANGPTL4 acts as a gatekeeper in the regulation of intestinal lipid uptake to protect against enterocyte lipid overload [7] . Expression of ANGPTL4 in the intestinal tract is sensitively stimulated by specific probiotic bacteria and short-chain fatty acids, while conventionalization of germ-free mice allegedly suppresses the expression of Angptl4 in the intestine [64] [65] [66] [67] [68] [69] [70] . Exactly how the microbial community affects intestinal Angptl4 expression and how changes in intestinal Angptl4 expression in turn affect intestinal lipid metabolism and the microbial community remains to be investigated.
ANGIOPOIETIN-LIKE 8
In 2012, three research groups independently identified ANGPTL8 -also referred to as refeedinginduced fat and liver, lipasin and betatrophin -as a novel lipid-modulating member of the ANGPTL family with a high homology to ANGPTL4 and ANGPTL3 [4, 71, 72] . ANGPTL8 has the characteristic N-terminal coiled-coil domain required for the inhibition of lipase activity but lacks the C-terminal fibrinogen-like domain [4, 71, 72] . In vitro, a clear dose-dependent inhibitory effect of recombinant ANGPTL8 on LPL activity was found [71] . ANGPTL8 and ANGPTL3 likely have a shared origin, as both genes are located in introns of genes from the DOCK family [4, 71, 72] . However, the tissue distribution of ANGPTL8 is more similar to that of ANGPTL4, with relatively high expression levels in liver and adipose tissue [4, 71, 72] . In contrast to Angptl4, expression of Angptl8 in liver and adipose tissue is highest in the (re)fed state [4, 72] .
Similar to ANGPTL3 and ANGPTL4, ANGPTL8 was found to associate with plasma HDL cholesterol and triglyceride levels in a study that focused on low-frequency DNA sequence variants and rare alleles [3 & ]. In the Dallas Heart Study, the R59W gene variant was associated with reduced plasma LDL and HDL cholesterol levels but not triglycerides [4] . Following these findings, multiple studies have tried to link plasma ANGPTL8 levels to various lipid and metabolic parameters. So far, the results have been contradictory. One serious concern is that the specificities of the ELISAs used to measure ANGPTL8 have been insufficiently established, casting doubt on the validity of the data [73] [74] [75] [76] [77] [78] .
Several studies in mice have demonstrated a pronounced effect of ANGPTL8 on LPL activity and plasma triglyceride levels, which is mainly evident in the fed state. Adenoviral-mediated overexpression of ANGPTL8 in liver significantly raised plasma triglyceride and free fatty acid levels [4, 71] . Conversely, whole body knock-out of Angptl8 and antibody-mediated inactivation of ANGPTL8 in mice increased postheparin LPL activity and lowered plasma triglyceride levels [79 & ,80] . As briefly noted previously, ANGPTL8 and ANGPTL3 likely cooperate to regulate plasma triglyceride levels, which is largely based on the observation that adenoviral overexpression of ANGPTL8 increased plasma triglyceride levels in wild-type but not Angptl3 -/-mice [4, 80] . In line with a predominant role of ANGPTL8 in the fed state, loss of Angptl8 significantly lowered the increase in VLDL-derived triglyceride uptake in adipose tissue upon refeeding, suggesting that ANGPTL8 promotes the postprandial flux of triglycerides into adipose tissue [80] . Even though Angptl8 expression is much higher in adipose tissue than in heart and muscle, loss of Angptl8 or antibody-mediated inactivation of ANGPTL8 increased LPL activity in heart and muscle but not in WAT [4,72,79 & ,80] . Another intriguing observation is that both feeding and cold exposure lead to a parallel increase in Angptl8 expression and LPL activity in WAT and BAT, respectively [4, 35, 37 && , 72, 81] . These data suggest that ANGPTL8 serves to fine-tune LPL activity and may be unable to overcome the dominant inhibitory effect on LPL activity by ANGPTL4. Alternatively, ANGPTL8 may mainly have an endocrine function. In agreement with that notion, ANGPTL8 has been reported to circulate as part of high molecular weight complexes in the blood together with ANGPTL3 [4, 80] .
Apart from regulating triglyceride metabolism, ANGPTL8 has also been linked to pancreatic b-cell function. Specifically, it was suggested that ANGPTL8 stimulates b-cell expansion, generating considerable excitement and turning ANGPTL8 into a promising therapeutic target for the treatment of diabetes [82] . Several subsequent studies have failed to detect an effect of ANGPTL8 on glucose metabolism and/or b-cell expansion [80,83-84,85 & ,86] . Indeed, faced with the overwhelming contradictory evidence, the initial authors acknowledged that the consequences of ANGPTL8 deletion do not support the idea that ANGPTL8 is capable of inducing pancreatic b-cell proliferation [87] .
INTEGRATED VIEW OF THE ROLE OF ANGPTL3, ANGPTL4 AND ANGPTL8 IN LIPID METABOLISM
The recent literature leads to the emergence of a collective picture in which ANGPTL3, ANGPTL4 and ANGPTL8 together ensure that circulating triglycerides are adequately distributed during different physiological conditions. Circulating ANGPTL3 and ANGPTL8 together promote the replenishment of WAT in the fed state by inhibiting LPL activity and subsequent uptake of circulating triglycerides into oxidative tissues [4,29 && ,80]. Conversely, ANGPTL4 prevents the uptake of plasma triglycerides into WAT and other tissues in the fasted state, while at the same time stimulating adipose tissue lipolysis, thereby favoring the use of free fatty acids as fuel [35, 88] ( Fig. 1) . During exercise and cold exposure, alterations in local expression of Angptl4 and concomitant changes in LPL activity ensure that muscle and BAT receive an adequate supply of triglycerides, reflecting an overall role of ANGPTL4 to specifically shuttle plasma triglycerides to the tissues in need [35,37 && ,49 && ]. Whether ANGPTL3 and ANGPTL8 impact the distribution of plasma triglycerides during exercise and cold exposure remains an open question. Nevertheless, it is likely that LPL activity levels in different tissues and during different physiological conditions reflect a balance between the systemic effects of circulating ANGPTL3 and ANGPTL8 and the local effects of ANGPTL4. To what extent the fluctuations in LPL activity during different physiological conditions are primarily dictated by regulation of ANGPTLs or are also partially achieved via variation in the production of LPL-inhibiting or LPLactivating apolipoproteins such as the apolipoprotein Cs, apolipoprotein A5 or APOE remains to be determined [89] . This inhibition ensures that circulating triglycerides are hydrolyzed by LPL and that the resultant fatty acids are subsequently taken up into heart and muscle. Upon refeeding (right panel), the expression of Angptl4 is decreased in WAT, whereas the expression of the circulating factor Angptl8 is increased in both liver and WAT. Together with circulating ANGPTL3, ANGPTL8 specifically inhibits the activity of LPL in oxidative tissues such as heart and muscle. This inhibition permits for the hydrolysis of circulating triglycerides by LPL in WAT and promotes the replenishment of WAT depots upon refeeding. ]. Furthermore, a conjugated antisense oligonucleotide against ANGPTL3 from Ionis pharmaceuticals successfully lowered plasma triglyceride levels in healthy individuals in phase I clinical trials and will be evaluated in a phase 1/2 clinical study [90] . The position of ANGPTL4 as a pharmacological target remains uncertain. In a recent study, a human monoclonal antibody (REGN1001) inhibiting ANGPTL4 was shown to effectively lower plasma triglyceride levels in mice and cynomolgus monkeys on a high-fat diet [47 && ]. However, in several mice and monkeys, treatment with REGN1001 resulted in the appearance of lipid-filled Touton cells in enlarged mesenteric lymph nodes, a condition that has been previously associated with a proinflammatory state and progressive illness involving chylous ascites, cachexia and death in Angptl4 -/-mice and in mice treated with anti-ANGPTL4 antibodies [45,47 && ,91] . It is noteworthy that no significant increase in diagnosis rates for lymphatic disorders, ascites, peritonitis or diarrhea was observed in carriers of the ANGPTL4-inactivating gene variant E40K compared with noncarriers [47 && ]. Nevertheless, the observed side-effects of treatment of primates with anti-ANGPTL4 antibodies raise serious concerns about the safety of targeting ANGPTL4 in humans.
The current status of ANGPTLs as therapeutic targets for dyslipidemia warrants further investigation into the biology of ANGPTL3, ANGPTL4 and ANGPTL8. An important outstanding question relates to the nature of the cooperation between ANGPTL3 and ANGPTL8. In addition, the role of local versus systemic ANGPTL4 and ANGPTL8 in the regulation of extracellular lipase activity deserves further study. Resolving these questions and other questions postulated in this review would greatly benefit from the generation of double knock-out mice and tissue-specific knock-out mice of the three ANGPTLs. Together, these efforts should further elucidate the specific role of ANGPTL3, ANGPTL4 and ANGPTL8 in lipid metabolism and provide a solid foundation for further clinical research on ANGPTL-targeting therapeutics as treatment for dyslipidemia.
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